CLINICALVX

VX DEVELOPMENT FOR PSYCHEDELIC THERAPIES

Premium VX Content R&D and Production.

Whether for Psilocybin, MDMA, LSD, DMT, Ketamine or Ibogane, VPI’s leadership in digital therapeutics, our deep background developing clinical trials using VR, and our years of success treating PTSD, ADHD and other mental health concerns with Clinical VR, position us to develop Premium Clinical VR / Immersive content exposures that can pair elegantly with medical psychedelic treatment to maximize desired impact and effect.

PHASE 1

DISCOVERY

Discovery period to understand research protocols and approach, analyze desired effects, and distil content parameters for VX R&D.

PHASE 2

R&D

Research and Development of VX content engineered to maximize treatment efficacy of the substance and target ailment.

PHASE 3

PRODUCTION

Prodution of a suite of Virtual Experience exposures for use in clinical trials, followed by trial execution.

Language »